Literature DB >> 25630365

Priapism as a result of chronic myeloid leukemia: case report, pathology, and review of the literature.

Osama Kamal Zaki Mahmoud Shaeer1, Kamal Zaki Mahmoud Shaeer, Islam Fathy Soliman AbdelRahman, Mostafa Shawky El-Haddad, Osama Mohamed Selim.   

Abstract

INTRODUCTION: Priapism is rare-presenting feature in male patients with chronic myeloid leukemia (CML). Several hypotheses for pathogenesis have been described. Management has been controversial; some authors described resolution following priapism-specific interventions, and others recommended addition of CML-specific therapy or even CML-specific therapy alone. AIM: In this report, we describe presentation and management of a man with refractory priapism that was the first presenting manifestation of CML. We also report, for the first time, the pathology sections of the sinusoidal tissue in such cases. Literature is reviewed for similar cases and their outcome.
METHODS: A 21-year-old male patient presented with painful priapism that started 6 days earlier and failed aspiration-irrigation. CBC revealed marked leucocytosis. Oncology care diagnosed CML, and treatment with Imatinib was commenced with prior semen cryopreservation. Following remission, a penile prosthesis was implanted, assisted by optical corporotomy. Sinusoidal tissue biopsy was stained by hematoxylin/eosin (H&E) and CD34. MAIN OUTCOME MEASURES: Pathology sections of cavernous tissue following CML-induced priapism.
RESULTS: The penile implant survived without complications. H&E examination of the sinusoidal tissue biopsy revealed leukemic infiltration associated with vascular endothelial damage. CD34 staining showed the mixed picture of leukemic infiltrates, intact vascular endothelium with lumena showing leukemic cells, alternating with destroyed vessels, and no vascular lumena and ruminants of endothelial cells.
CONCLUSION: Priapism can be the first manifestation of previously undetected CML. The pathological picture of sinusoidal tissue in such cases is presented. In the case at hand, a complete blood picture was helpful in early diagnosis of CML and early initiation of targeted chemotherapy along with the corporal irrigation/aspiration or shunt surgery. It is therefore recommended to have a CBC examined at presentation of any case of ischemic priapism of unknown etiology, early initiation of CML therapy along with aspiration/irrigation, preferably cryopreserving a semen sample before CML therapy.
© 2015 International Society for Sexual Medicine.

Entities:  

Keywords:  CML; Chronic Myeloid Leukemia; Priapism

Mesh:

Substances:

Year:  2015        PMID: 25630365     DOI: 10.1111/jsm.12812

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  6 in total

1.  Comparison of outcomes in malignant vs. non-malignant ischemic priapism: 12-year experience from a tertiary center.

Authors:  Manoj Kumar; Gaurav Garg; Ashish Sharma; Siddharth Pandey; Manmeet Singh; Satya Narayan Sankhwar
Journal:  Turk J Urol       Date:  2019-02-20

Review 2.  Review of Ischemic and Non-ischemic Priapism.

Authors:  Mark G Biebel; Martin S Gross; Ricardo Munarriz
Journal:  Curr Urol Rep       Date:  2022-05-10       Impact factor: 3.092

Review 3.  Malignant Priapism - What Do We Know About It?

Authors:  Dragos Marcu; Lucian Iorga; Dan Mischianu; Nicolae Bacalbasa; Irina Balescu; Ovidiu Bratu
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

Review 4.  Clinical Management of Priapism: A Review.

Authors:  Kazuyoshi Shigehara; Mikio Namiki
Journal:  World J Mens Health       Date:  2016-04-30       Impact factor: 5.400

5.  Priapism secondary to chronic myeloid leukemia treated by a surgical cavernosa-corpus spongiosum shunt: Case report.

Authors:  Min Qu; Xin Lu; Lei Wang; Zhiyong Liu; Yinghao Sun; Xu Gao
Journal:  Asian J Urol       Date:  2018-12-15

6.  Priapism as the initial sign in hematologic disease: Case report and literature review.

Authors:  Luis Cuitláhuac Becerra-Pedraza; Luis Enrique Jiménez-Martínez; Iran Peña-Morfin; Rogelio Nava-Esquivel; Juan Alfredo Villegas-Martínez
Journal:  Int J Surg Case Rep       Date:  2018-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.